Topical medications on dermabraded tattoos

1970 ◽  
Vol 102 (4) ◽  
pp. 438-439
Author(s):  
R. D. Hagerman
Keyword(s):  
Topical Medications

RADT-13. SPARE TRIAL: SCALP-SPARING RADIATION WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi43-vi44
Author(s):  
Ryan Miller ◽  
Andrew Song ◽  
Ayesha S Ali ◽  
Voichita Bar-Ad ◽  
Nina, L Martinez ◽  
...  
Keyword(s):  
Radiation Treatment ◽  
Methylation Status ◽  
Treatment Interruption ◽  
Newly Diagnosed ◽  
Entire Cohort ◽  
Tumor Treating Fields ◽  
Newly Diagnosed Glioblastoma ◽  
Prospective Trials ◽  
Dose Constraints ◽  
Topical Medications

Abstract INTRODUCTION Current adjuvant treatment for patients with newly diagnosed glioblastoma includes concurrent chemoradiation and maintenance temozolomide with Tumor Treating Fields (TTFields). We report our clinical trial evaluating feasibility and tolerability of scalp-sparing radiation with concurrent temozolomide and TTFields. METHODS Adult patients (age ≥ 18 years) with newly diagnosed glioblastoma with a KPS of ≥ 60 were eligible. All patients received concurrent scalp-sparing radiation (60 Gy in 30 fractions) with temozolomide (75 mg/m2 daily) and TTFields (200 kHz). Maintenance therapy included temozolomide and continuation of TTFields. Radiation treatment was delivered through TTFields arrays. The primary endpoint was safety and toxicity of tri-modality treatment within 30 days of completion of chemoradiation treatment. RESULTS Thirty patients were enrolled. Twenty were male and ten were female, with a median age of 58 years (range 19 to 77 years). Median follow-up was 10.8 months (range 1.6 to 21.3 months). Twenty (66.7%) patients had unmethylated MGMT promotor and ten (33.3%) patients had methylated promoter. Scalp dose constraints were achieved for all patients. Skin adverse events (erythema, dermatitis, irritation, folliculitis) were noted in 83.3% of patients, however, these were limited to Grade 1 or 2 events, which resolved spontaneously or with topical medications. No patient had radiation treatment interruption due to skin AEs. Other Grade 1 events included pruritus (33.3%), fatigue (30%), nausea (13.3%), headache (10%), dizziness (6.7%), and cognitive impairment (3.3%). Other Grade 2 events included headache (3.3%). The median PFS for the entire cohort was 9.1 months (at least 8.5 months, 95% confidence). The median PFS for patients with MGMT promoter methylation status was 11.4 months (at least 9.5 months, 95% confidence). Overall survival was not reached. CONCLUSIONS Concurrent TTFields with scalp-sparing chemoradiation is feasible treatment option with limited toxicity. Future randomized prospective trials are warranted to define therapeutic advantages of concurrent TTFields with chemoradiation.

scholarly journals Treatment of Pyodermatitis-Pyostomatitis Vegetans: A Systematic Review and Meta-analysis

2021 ◽  
Vol 5 (4) ◽  
pp. 333-346
Author(s):  
Landon Kaleb Hobbs ◽  
Alina Zufall ◽  
Shadi Khalil ◽  
Richard Flowers
Keyword(s):  
Case Reports ◽  
Meta Analysis ◽  
Case Series ◽  
Calcineurin Inhibitors ◽  
Additional Patient ◽  
Aminosalicylic Acid ◽  
First Line Therapy ◽  
Pyostomatitis Vegetans ◽  
Oral Corticosteroids ◽  
Topical Medications

Background: Pyodermatitis-pyostomatitis vegetans (PDV-PSV) is a rare muco-cutaneous disorder characterized by vegetating and pustular plaques and is often associated with inflammatory bowel disease (IBD). The purpose of this study was to systematically identify and analyze reports of PDV-PSV to determine the most effective treatment. Methods: Reports of PDV-PSV were identified using the OVID-Medline database from inception through November 2019. Publications were excluded if no new patient case was included, if there was not clinical and histological evidence of PDV, PSV, or PDV-PSV, or if no treatment was discussed. Results: The final sample was comprised of 74 publications plus an additional patient from the authors’ institution, corresponding to 95 total patients. The basis of the review and analysis is limited to case reports and case series, which likely only report the cases with positive outcomes. Statistical analysis revealed that oral corticosteroids (OCS), 6-mercaptopurine/azathioprine, oral calcineurin inhibitors (OCNI), 5-aminosalicylic-acid (5-ASA), and biologics (BIO) were the most effective treatments for PDV-PSV. Topical medications, colchicine, oral dapsone, and other antibiotics were ineffective treatments, with topical medications being the least effective option. When OCS are used, they work best when used as initial treatment to induce remission. 5-ASA and BIO are most effective when used as maintenance therapies after initial remission. Conclusions: Thus, first line therapy for PDV-PSV should begin with OCS with transition to steroid-sparing agents including OCNI, BIO, and 5-ASA if indicated.  

Allergy due to topical medications in chronic otitis externa and chronic otitis media

1995 ◽  
Vol 20 (4) ◽  
pp. 326-328 ◽  
Author(s):  
C. J. W. VAN GINKEL ◽  
Tj. D. BRUINTJES ◽  
E. H. HUIZING
Keyword(s):  
Otitis Media ◽  
Otitis Externa ◽  
Chronic Otitis Media ◽  
Topical Medications

TOPICAL MEDICATIONS FOR OROFACIAL NEUROPATHIC PAIN: A REVIEW

2000 ◽  
Vol 131 (2) ◽  
pp. 184-195 ◽  
Author(s):  
MARIELA PADILLA ◽  
GLENN T. CLARK ◽  
ROBERT L. MERRILL
Keyword(s):  
Neuropathic Pain ◽  
Topical Medications

Pharmacologic Management of Foot Pain in the Older Patient

2004 ◽  
Vol 94 (2) ◽  
pp. 98-103 ◽  
Author(s):  
Edward W. Martin
Keyword(s):  
Pain Treatment ◽  
Treatment Strategies ◽  
Persistent Pain ◽  
Foot Pain ◽  
Loss Of Function ◽  
Significant Disability ◽  
Pharmacologic Management ◽  
Inflammatory Drugs ◽  
Topical Medications ◽  
Cyclooxygenase 2 Inhibitors

Foot pain, if not effectively managed, can result in significant disability and loss of function in older patients. This article reviews treatment strategies for acute and persistent pain, emphasizing new pharmacologic approaches. Indications, guidelines, and precautions for acute-pain treatment with acetaminophen, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and opioids are discussed. Strategies for management of persistent pain using opioids, tricyclic antidepressants, gabapentin, and topical medications are reviewed. Common pain-management and prescribing errors are highlighted. (J Am Podiatr Med Assoc 94(2): 98-103, 2004)

Topical Medications in Vitiligo

2017 ◽  
pp. 255-266
Author(s):  
Koushik Lahiri ◽  
Anupam Das
Keyword(s):  
Topical Medications
Sign in / Sign up

Export Citation Format

Share Document